CN116349815A

CN116349815A - Production formula of viable bacteria type probiotic solid beverage capable of regulating intestinal flora

Info

Publication number: CN116349815A
Application number: CN202111621127.1A
Authority: CN
Inventors: 沈云; 扈晓佳; 董思萱; 过文渊; 刘巧红; 陈杰娜; 周鲁浩
Original assignee: Natural Sunshine Shanghai Commodity Co ltd
Current assignee: Natural Sunshine Shanghai Commodity Co ltd
Priority date: 2021-12-28
Filing date: 2021-12-28
Publication date: 2023-06-30

Abstract

The invention discloses a production formula of a live bacteria type probiotic solid beverage capable of regulating intestinal flora, which comprises the following components in parts by weight: 5-50 parts of lactitol, 10-40 parts of inulin, 2-11 parts of fructo-oligosaccharide, 3-11 parts of lactobacillus powder, 1-11 parts of strawberry fruit powder and 0.3-2.0 parts of calcium silicate; the lactobacillus powder is a mixture of animal bifidobacterium Bb-12, lactobacillus bifidobacterium B420 and lactobacillus acidophilus NCFM; wherein the active concentration of the bifidobacterium animalis Bb-12 is 10-400 hundred million CFU/bag; the active concentration of bifidobacterium lactis B420 is 8-300 hundred million CFU/bag; the active concentration of lactobacillus acidophilus NCFM is 10-200 hundred million CFU/bag, the product is in the form of powder, and the edible dose is 2-6 g per day. The compound probiotic solid beverage can be used as common food, has good taste and safety, is suitable for long-term administration, contains various probiotics and prebiotics, and has good probiotic activity and synergy.

Description

Production formula of viable bacteria type probiotic solid beverage capable of regulating intestinal flora

Technical Field

The invention relates to the field of preparation of composite live bacteria type probiotic solid beverage, in particular to a production formula of a live bacteria type probiotic solid beverage capable of regulating intestinal flora.

Background

A large number of microorganisms live in the intestinal tract of a normal human body, the total weight of the intestinal tract is about 1.5 kg, the intestinal tract contains about millions of bacteria, the number of the intestinal tract is ten times of that of human cells, and the total number of genes is 100 times of that of the human body. Scientists find that at least 1000 microorganisms exist in the human gut, which are closely related to our health. There are at least 160 dominant bacterial groups per person. Of the gastrointestinal bacteria of healthy humans, more than 90% of the species of the phylum bacteroides and firmicutes include bacteroides, praecox, porphyromonas, clostridium, eubacterium, lactobacillus, and the like. Other less abundant species are actinomycetes (bifidobacterium and chrysogenum), proteus (enterobacteriaceae, helicobacter pylori, etc.), wart micro-bacteria, methanogenic archaea, etc.

Bacteria in the intestinal tract can be classified into beneficial bacteria, neutral bacteria and harmful bacteria. Beneficial bacteria can regulate intestinal immunity, inhibit growth of harmful bacteria, and help organism to remove substances such as intestinal toxins secreted by harmful bacteria. Harmful bacteria secrete intestinal toxins, causing intestinal inflammation and other systemic metabolic diseases. The relationship between the intestinal flora and the human body is complicated, and the intestinal flora and the human body are penetrated through various physiological activities and pathological processes of the human body and become an indispensable part of the human body. Intestinal flora of healthy people are mutually balanced, and participate in regulating balance and stabilization of human immunity, endocrine, nerve and digestive system. Once the host and external environment change, or improper dietary structure such as high energy or low fiber diet, results in physiological and pathological combinations, resulting in dysbacteriosis of the intestinal flora. The dysbacteriosis of intestinal canal leads to decrease of beneficial bacteria, increase of pathogenic bacteria, barrier disorder of intestinal mucosa, increase of intestinal permeability, and bacteria and antigens thereof are easy to induce abnormal immune reaction through intestinal mucosa, release a large amount of inflammatory factors and various active substances, further cause overgrowth of bacteria, influence intestinal movement, influence absorption of fat and sugar, and finally cause a series of clinical symptoms such as abdominal pain, diarrhea, abdominal distension and the like; or promote fat deposition, change metabolism, break energy homeostasis, and finally lead to the occurrence of insulin resistance and type 2 diabetes. With the recent intensive research, there is also increasing evidence of the relevance of microorganisms to human health.

Flora detection is currently used in clinical practice for pathogen detection, but there is little guidance in nutrition and chronic disease detection. Detecting intestinal flora, knowing the composition of the intestinal flora, and providing a new way for individual health assessment and disease prevention in the future in the aspects of human chronic disease risk prediction, accurate regulation of the intestinal flora, healthy diet suggestion and the like.

Through collecting fecal DNA, verifying an experimental method based on a bacterial 16sRNA sequence, performing DNA purification on parameters of each detection index according to bioinformatics comparison of bacterial evolution, detecting according to each index by using a fluorescent quantitative PCR technology, and finally calculating the richness of corresponding bacteria in intestinal tracts according to detection results, so that health evaluation can be performed on individuals.

Probiotics are active microorganisms that can exert health benefits when ingested in appropriate amounts by a host. The most common probiotic bacteria are lactic acid bacteria, including lactobacillus, enterococcus and bifidobacteria. The probiotics not only can promote the metabolism of nutrient substances, but also can improve the absorption and utilization of vitamins and minerals by human bodies, and have various functions of promoting digestion, preventing constipation and the like. Each probiotic strain has its own unique health benefits, and when one probiotic strain has a certain health benefit, another strain that does not represent the same species also has similar properties. A combination of different probiotic strains may produce a number of beneficial effects.

The prebiotics refer to a non-digestible substance which can be used as a substrate by normal flora of the intestinal tract and can selectively stimulate the growth and activity of one or more existing probiotics in the intestinal tract and inhibit the growth of harmful bacteria, so that the prebiotics have important effect on restoring the ecological balance of the intestinal flora. Common prebiotics include inulin, fructo-oligosaccharides, galacto-oligosaccharides, soy oligosaccharides, xylo-oligosaccharides and the like.

The Chinese patent with publication number of CN 201010292562.X discloses a medicine for improving the balance of intestinal flora of human body and a preparation method thereof, wherein the medicine comprises the following components: the extract takes 4-10 parts of dried orange peel, 10-30 parts of fried white hyacinth bean, 10-30 parts of poria cocos, 5-20 parts of wrinkled gianthyssop herb, 7-25 parts of lotus leaf and 7-25 parts of dandelion as raw materials; and 200-400 parts of fructo-oligosaccharides; the weight proportion is as above. However, this is not a common food, and long-term administration may affect the normal flora in the intestinal tract.

Disclosure of Invention

In order to overcome the defects in the prior art, the invention aims to provide a viable probiotic solid beverage production formula capable of regulating intestinal flora. The formula has good taste and safety, is suitable for long-term administration, contains various probiotics and prebiotics, and has good activity and synergy of the probiotics.

The production formula of the viable bacteria type probiotic solid beverage capable of regulating intestinal flora comprises the following components in parts by weight:

5-50 parts of lactitol, wherein the weight of the lactitol is equal to that of the mixture,

10-40 parts of inulin, which is prepared from the following raw materials,

2-11 parts of fructo-oligosaccharide,

3-11 parts of lactobacillus powder,

1-11 parts of flavor adjusting material,

0.3-2.0 parts of calcium silicate;

the lactobacillus powder is a mixture of animal bifidobacterium Bb-12, lactobacillus bifidobacterium B420 and lactobacillus acidophilus NCFM;

wherein the active concentration of the bifidobacterium animalis Bb-12 is 10-400 hundred million CFU/bag;

the active concentration of bifidobacterium lactis B420 is 8-300 hundred million CFU/bag;

the active concentration of lactobacillus acidophilus NCFM is 10-200 hundred million CFU/bag, the product is in the form of powder, and the edible dose is 2-6 g per day.

In a preferred embodiment of the invention, the fraction of lactitol is 38-50 parts.

In a preferred embodiment of the invention, the fraction of inulin is 20-40 parts.

In a preferred embodiment of the invention, the fraction of fructooligosaccharides is 7.5-11 parts.

In a preferred embodiment of the invention, the part of the lactic acid bacteria powder is 4-8 parts.

In a preferred embodiment of the present invention, the flavor modifying material is strawberry fruit powder, and the portion of the strawberry fruit powder is 4-6 portions.

The invention has the beneficial effects that:

the compound probiotic solid beverage can be used as common food, has good taste and safety, is suitable for long-term administration, contains various probiotics and prebiotics, and has good probiotic activity and synergy.

Detailed Description

The invention is based on the following principle:

1. the taste of the strawberry brought by the natural strawberry powder is improved by natural ingredients, so that the strawberry powder is convenient to take continuously.

2. The three selected strains, namely the bifidobacterium animalis Bb-12, the lactobacillus acidophilus NCFM and the bifidobacterium lactis B420, belong to strains in the 2012 ministry of health edible in a strain list of foods and can be used for food production and processing, wherein the bifidobacterium animalis Bb-12 and the lactobacillus acidophilus NCFM are also recorded in the 2011 ministry of health established strain list for infant foods. In addition, bifidobacterium animalis Bb-12, lactobacillus acidophilus NCFM and bifidobacterium lactis B420 were both certified as us Generally Recognized As Safe (GRAS). Inulin is a new resource food raw material, other components belong to common food raw materials, and the product has good safety and is suitable for long-term eating.

Lactitol, inulin and fructo-oligosaccharide are all prebiotics, and can promote growth and propagation of probiotics in intestinal tracts. In addition, the lactitol and the fructo-oligosaccharide can provide pure sweet taste, have low calorie, are not easy to cause blood sugar rise and obesity, and can be used as a filling agent and a carrier to improve the production feasibility of the probiotic powder. Too much lactitol and fructo-oligosaccharides may make the product taste too sweet, too little may make the sweetness too light and not exert its proliferation effect on probiotics to the maximum extent, and may even affect the feasibility of production and processing.

3. Research shows that lactobacillus acidophilus needs acetate, vitamin B2, folic acid and the like as nutrient substances in growth, and bifidobacteria can synthesize various vitamins such as vitamin B1, vitamin B2, vitamin B12, folic acid and the like in addition to acetic acid in fermentation, and just supply the requirements of lactobacillus acidophilus, so that the growth and proliferation of lactobacillus acidophilus are promoted, lactobacillus acidophilus grows fast in a micro-oxygenated milk matrix, the oxidation-reduction potential in the milk matrix can be gradually reduced, various decomposed substances which are easy to use are provided, and the growth of bifidobacteria is promoted. The product adopts the combination of bifidobacteria and lactobacillus acidophilus, can better utilize the intergrowth relationship thereof, and promotes the growth and propagation of the bifidobacteria and lactobacillus acidophilus in the gastrointestinal tract.

Clinical studies show that, after 30 days of continuous eating, 200 hundred million CFU lactobacillus acidophilus NCFM can obviously influence the expression of the receptor related to the pain of the colon mucosa of a human body, thereby relieving the intestinal pain problem. The lactobacillus acidophilus NCFM50 hundred million CFU dry powder is continuously eaten for 6 months and 2 times a day, and has remarkable effect on reducing fever, cough and nasal discharge symptoms. Clinical studies show that the mixture containing 100 hundred million CFU lactobacillus acidophilus NCFM and lactitol is eaten for 2 weeks, 2 times a day, the content of lactobacillus acidophilus NCFM in feces is obviously increased, and immune factor PGE is obtained ₂ IGA increases.

Clinical studies show that the content of the bifidobacterium lactis B420 in feces is obviously increased after eating the bifidobacterium lactis B420 for 5 weeks, the phagocytic activity of immune cells is enhanced, and the concentration of triglyceride in blood is reduced.

Clinical researches show that the capsule containing 10 hundred million CFU/granule of animal bifidobacterium Bb12 is eaten for 1 time per day and continuously eaten for 6 weeks, so that the level of immune factors can be improved, and the immunity of a human body can be enhanced. The capsule containing 100 hundred million CFU/granule of bifidobacterium animalis Bb12 is eaten every day, the occurrence risk of gestational diabetes is obviously reduced, and the capsule has no adverse reaction to fetuses and pregnant women.

If the addition amount of the viable bacteria is too low, the intestinal tract can be effectively reached, the number of the viable bacteria is limited, and the expected health benefit is difficult to achieve; if the addition amount of the live bacteria is too high, on one hand, the price may be too high, so that the common consumer is difficult to eat for a long time, on the other hand, the quantitative effect relationship between the too high probiotic administration amount and the health benefit is not verified, and whether the excessive eating can cause adverse reactions of the body is also to be verified.

4. 3 probiotics and 3 probiotics are selected, the probiotics can provide nutrition for growth and propagation of the probiotics, the selected 3 probiotics have wide intestinal coverage, and the beneficial effects of protecting and repairing the intestinal tract are more widely achieved.

5. Bifidobacteria species have been shown to adhere to epithelial cell lines and to assist in maintaining intestinal homeostasis. Aging and various diseases can reduce the proportion of bifidobacteria and the diversity of strains. In general, a higher proportion of bifidobacteria in the gut is considered to be beneficial for health and associated with the life stage. In vitro studies have demonstrated that bifidobacterium lactis B-420 is significantly tolerant to bile salts and acids. Clinical trials showed an increased content of bifidobacterium lactis in the faeces following ingestion of the strain bifidobacterium lactis B-420, which indicates that bifidobacterium lactis B-420 is still viable after passage through the gastrointestinal tract. Bifidobacterium lactis has been shown to inhibit the formation of membrane folds, protect tight junctions, and cancel transepithelial impedance reduction induced by gliadin in Caco-2 cells.

6. In vitro studies have demonstrated that bifidobacterium animalis Bb-12 is able to withstand low pH conditions similar to those in the stomach and to survive bile concentration conditions in the duodenum. Clinical studies show that the bifidobacterium animalis Bb-12 can reduce diarrhea of infants, improve intestinal flora of infants, improve defecation frequency of nursing home residents, and improve intestinal environment and fecal flora of old people. The bifidobacterium animalis Bb-12 can promote the level of immune factor IgA and has the functions of enhancing immunity and resisting inflammation for human bodies.

7. In vitro studies have shown that lactobacillus acidophilus NCFM is resistant to low pH conditions similar to the stomach, and also survives bile concentrations found in the duodenum, and its ability to adhere to different human epithelial cell lines has also been demonstrated in several studies. The results of the study showed that lactobacillus acidophilus NCFM in the feces after ingestion of the corresponding probiotic strain was significantly increased over a period of 2 months, thereby confirming its viability in the gastrointestinal tract. Lactobacillus acidophilus NCFM can reduce unnecessary fecal enzyme activity and other cancer related markers, improve lactose intolerance, reduce diarrhea incidence, improve overgrowth of small intestine bacteria, and participate in immune system regulation.

8. The invention is further illustrated by the following examples:

example 1:

47 parts of lactitol, 35 parts of inulin, 7.5 parts of fructo-oligosaccharide, 5 parts of lactobacillus powder, 4 parts of strawberry fruit powder and 1.5 parts of calcium silicate.

Wherein the lactobacillus powder comprises 12 parts of bifidobacterium animalis Bb, 5 parts of lactobacillus acidophilus NCFM and 420 parts of bifidobacterium lactis B.

Example 2:

40 parts of lactitol, 40 parts of inulin, 7.5 parts of fructo-oligosaccharide, 5 parts of lactobacillus powder, 6 parts of strawberry fruit powder and 1.5 parts of calcium silicate.

Example 3:

50 parts of lactitol, 26 parts of inulin, 11 parts of fructo-oligosaccharide, 5 parts of lactobacillus powder, 6 parts of strawberry fruit powder and 2 parts of calcium silicate.

The probiotic solid drink prepared in examples 1-3 was tested for mouthfeel.

The selection and assessment method of the assessment personnel comprises the following steps: the assessment panel consisted of 15 panelists with higher resolution and sensitivity to the color, aroma, taste of the food. The samples were coded with 2-digit random numbers and evaluated for preference at room temperature. Before the evaluation, the mouth is rinsed with warm water, and each time one sample is completely tasted, the mouth is rinsed with warm water before the next sample is tasted. The evaluation consisted of five dimensions of color, mouthfeel, odor, sweetness, acidity, each dimension divided into 10 points, favorability scores as shown in table 1 below:

TABLE 1

Like (9-10 min)

Preference (7-8 points)

General (5-6 min)

Poor (3-4 min)

Difference (1-2 points)

The sensory scoring results are shown in table 2 below,

table 2:

	color (10 min)	Mouthfeel (10 minutes)	Smell (10 minutes)	Sweetness (10 minutes)	Acidity (10 min)
						Example 1	6.5	8.4	9.2	7.6	6.9
Example 2	8.3	9.2	9.6	7.9	7.8
						Example 3	9.1	8.6	9.8	8.3	8.7

Application example 1:

the stability of the live bacteria type probiotic solid drink prepared by the formula shown in the example 3 is examined, an aluminum foil bag is sealed, 2 g/bag is placed at 25+/-3 ℃ and 60%RH+/-5%RH for 3 months, and the total live bacteria number of each bag of sample is measured respectively at 0 month, 1 month, 2 months and 3 months. The results are shown in Table 3 below:

TABLE 3 Table 3

The stability results show that the viable bacteria count of the viable bacteria type probiotic solid beverage is most obviously reduced within 1 month after just preparing, but is basically stabilized to about 500 hundred million CFU/bag from the first month to the 3 rd month, and the viable bacteria type probiotic solid beverage has better stability and can keep higher activity after being placed at normal temperature.

Application example 2:

the living bacteria type probiotic solid drink can regulate intestinal flora and relieve gastrointestinal discomfort after being taken for 1 month.

Short-term human intestinal flora detection test: 10 subjects were randomly selected and the test used in self-control. The subjects consumed 2 bags (2 g/bag) of live-fungus-type probiotic solid drink daily, and took the drink according to the formula shown in example 3, once in the morning and afternoon, for 30 days continuously.

Before the test substance is eaten and within a week after the last administration of the test substance, the clean cotton swabs are respectively used for taking the about stool and the about mung bean size of the test subject, and the test subjects are placed in a MAP intestinal flora detection kit, and the kit is collected and sent to a detection company for detection. Analysis was performed as a relative percentage of the number of intestinal flora and statistics were observed on subjective symptoms before and after consumption by the subjects.

By analyzing the composition of the flora in the faecal sample before and after 1 month of taking the product, the composition percentages of the flora are shown in table 4 below:

TABLE 4 Table 4

Remarks: * Represents P <0.05, and P <0.01.

Subjective symptom observation of the tested population: after the subjects drink the test objects, all the subjects have no adverse reaction, the constipation of 6 people is improved, the appetite of 7 people is increased, and the exhaust of 5 people is increased.

Application example 3:

the living bacteria type probiotic solid drink can regulate intestinal flora and relieve gastrointestinal discomfort after being taken for 3 months.

Short-term human intestinal flora detection test: 12 subjects were randomly selected and the test used in its own control. The subjects consumed 2 bags (2 g/bag) of live-fungus-type probiotic solid drink daily, and took the drink according to the formula shown in example 3, once in the morning and afternoon, and continuously for 90 days.

Before the test substance is eaten and within a week after the last administration of the test substance, the clean cotton swabs are respectively used for taking the about stool and the about mung bean size of the test subject, and the test subjects are placed in a MAP intestinal flora detection kit, and the kit is collected and sent to a detection company for detection. Analysis was performed as a relative percentage of the number of intestinal flora and statistics were observed for subjective symptoms before and after consumption by the subjects, with the statistics shown in table 5 below:

TABLE 5

Remarks: * Represents P <0.01.

Subjective symptom observation of the tested population: after the subjects drink the test objects, all the subjects have no adverse reaction, the constipation condition of 9 people is improved, the appetite of 8 people is increased, and the exhaust of 5 people is increased.

From the above tables 3 to 5, it can be seen that the population to be tested drinks the live bacteria type composite probiotic solid drink for 30 days, and the beneficial bacteria in the intestinal tract of the population to be tested are increased, including bifidobacteria, lactobacillus, akkermansia muciniphila (mucin-Acremonium), clostridium tender and bacteroides thetaiotaomicron enterobacteria; wherein the bifidobacterium content is significantly increased (P < 0.05); neutral bacteria include enterobacteria and reduced content of Fusobacterium nucleatum. The living bacteria type composite probiotic solid beverage disclosed by the invention can increase beneficial bacteria in human intestinal tracts, reduce enterobacteria and fusobacterium nucleatum and has an improvement effect on human intestinal flora. And the product has the effects of improving intestinal flora and enhancing physique by observing subjective symptoms of the tested population.

Claims

1. The production formula of the viable bacteria type probiotic solid drink capable of regulating intestinal flora is characterized by comprising the following components in parts by weight:

10-40 parts of inulin, which is prepared from the following raw materials,

2-11 parts of fructo-oligosaccharide,

3-11 parts of lactobacillus powder,

1-11 parts of strawberry fruit powder,

0.3-2.0 parts of calcium silicate;

2. A live bacterial probiotic solid beverage production formulation capable of regulating intestinal flora according to claim 1, wherein the fraction of lactitol is 38-50.

3. A live bacterial probiotic solid beverage production formulation capable of regulating intestinal flora according to claim 1, wherein the fraction of inulin is 20-40.

4. A live bacterial probiotic solid beverage production formulation capable of regulating intestinal flora according to claim 1, wherein the fraction of fructooligosaccharides is 7.5-11.

5. A live bacterial probiotic solid beverage production formula capable of regulating intestinal flora according to claim 1, wherein the lactic acid bacteria powder is 4-8 parts.

6. The formulation for producing a viable probiotic solid beverage capable of regulating intestinal flora according to claim 1, wherein the flavor-adjusting material is strawberry fruit powder, and the strawberry fruit powder is 4-8 parts.